← Back to headlines
ORIC Stock Rises as Stifel Resumes 'Buy' Rating Ahead of Pfizer Readout
ORIC Pharmaceuticals saw its stock gain after Stifel resumed its coverage with a 'Buy' rating, anticipating an upcoming readout from Pfizer.
12 Jun, 16:21 — 12 Jun, 16:21
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Pagcor Launches P60-M Scholarship Fund for Bulacan Students
just now
Manila Water Ensures 24/7 Service Amid El Niño Through Low Nonrevenue Water
just now
Nigeria's Galaxy Backbone Attracts Banks After Data Localization Directive
just now